Skip to content
Parakho

Symbiotec Pharmalab Ltd

NSE SYMBIOTECBSE 544889symbiotec.com

Q1 FY27, unaudited

Revenue
₹210.84 Cr
Profit after tax
₹47.01 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year ago—
Revenue from operations210.84——
Other income19.55——
Total income230.39——
Employee benefit expense35.22——
Finance costs5.62——
Depreciation & amortisation10.15——
Total expenses167.37——
Profit before tax63.02——
Tax expense16.01——
Profit after tax47.01——
Total comprehensive income46.96——
Earnings per share
Earnings per share, basic₹7.49—
Earnings per share, diluted₹7.49—

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Q1 FY27

Symbiotec Pharmalab reported consolidated revenue of Rs 218 crore for Q1 FY27, up 7% year-on-year, driven largely by its API business which grew 6% with gross margins above 60%. Consolidated EBITDA stood at Rs 45 crore and net profit at about Rs 14 crore, which management said were impacted by operating expenses and depreciation from the new biotech CDMO and complex injectables businesses that have not yet generated revenue. Management reiterated guidance of 20-25% growth in revenue and EBITDA for the fiscal year, with new business revenues expected to begin in the next 6 to 12 months.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Filings

12 shown · 20 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 05 Oct 2026.